News
Multiple myeloma is a type of blood cancer caused by a buildup of abnormal plasma cells in the bone marrow. As the abnormal plasma cells accumulate, they crowd out healthy cells and cause symptoms ...
2mon
Medpage Today on MSNFor Your Patients: What Is Multiple Myeloma?Multiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all ...
Her treatment consisted of rhubarb pills and an infusion of orange peels. Now, 181 years later, multiple myeloma remains incurable, with most patients eventually relapsing or developing treatment ...
So what you want to determine is, how serious is the multiple myeloma? How extensive is it? How is it affecting other organs? There's a big spectrum with multiple myeloma and all these plasma cell ...
Hosted on MSN1mon
How the Diagnosis of Multiple Myeloma Has EvolvedFor decades, the diagnosis of multiple myeloma required evidence of end-organ damage characterized by myeloma-defining events (MDEs) known as CRAB: Diagnosis also required -- and still does -- the ...
Multiple myeloma is a rare type of cancer. It starts with the uncontrolled production of plasma cells. These are a type of white blood cell in the bone marrow. Healthy plasma cells make antibodies ...
The addition of subcutaneous daratumumab to triplet therapy improved outcomes for certain patients with newly diagnosed multiple myeloma, study results showed. The vast majority of individuals who ...
It joins a number of other BCMA-directed therapies for multiple myeloma, including GSK's first-to-market antibody-drug conjugate Blenrep (belantamab mafodotin), Bristol-Myers Squibb/bluebird bio's ...
Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, prognosis, and therapeutic management of multiple myeloma. This new study in ...
But the pain persisted, so she scheduled an appointment with her doctor. Her diagnosis—multiple myeloma, a type of blood cancer—was unexpected. “I was stunned,” Flowers says.
The ability to eliminate specific pathologic cells is creating more options for multiple myeloma patients. Several targeting approaches are in development. BCMA is preferentially expressed on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results